SecBot SecBot
8-K ·Filed Jun 11, 2026

CRBU

Caribou Biosciences, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed5mo ago SEC0001619856-26-000043
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The vispa-cel 2L LBCL data (82% ORR, 17.1-month mPFS) strengthen the case for the pivotal ANTLER-3 phase 3 trial, which targets an underserved patient population. The CB-011 MM data (83% CR, early signal in BCMA-exposed patient) de-risks the dose expansion readout expected in H2 2026. Monitor for initial CB-011 dose expansion data in BCMA-naïve and -exposed patients in late 2026, which will be the next meaningful catalyst. Cash runway and ability to fully fund ANTLER-3 remain key risks not addressed in this filing.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$1.66
T+0 close · Jun 11, 2026 · via day close
Latest settled
+16.87%
T+20 · $1.94
Vs SPY
+14.98%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 11 $1.66entry
  2. T+1 · 5mo ago −3.92%α −4.46% · $1.60
  3. T+5 · 5mo ago −1.20%α −1.64% · $1.64
  4. T+20 · 4mo ago +16.87%α +14.98% · $1.94
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Caribou Biosciences announced long-term follow-up data from its ANTLER phase 1 (vispa-cel, anti-CD19) and CaMMouflage phase 1 (CB-011, anti-BCMA) trials at the EHA 2026 meeting. For vispa-cel in 2L LBCL (pivotal subgroup, N=27): 82% ORR, 67% CR, 17.1-month mPFS. For CB-011 in r/r MM (BCMA-naïve RDE cohort, N=12): 92% ORR, 83% CR, 91% MRD negativity. Both assets showed manageable safety profiles. The company also reiterated FDA alignment on the design of the ANTLER-3 pivotal phase 3 trial for vispa-cel. This data update is a notable but incremental catalyst for this pre-revenue clinical-stage biotech, positive efficacy readouts but from small, single-arm cohorts without financial guidance.

Key Facts

  • Vispa-cel in 2L LBCL (pivotal optimized subgroup, N=27): 82% ORR, 67% CR rate, 17.1-month median PFS
  • CB-011 in BCMA-naïve r/r MM at RDE (N=12): 92% ORR, 83% CR rate, 91% MRD negativity in 10/11 evaluable, 50% in CR at 15 months
  • CB-011 case study: 71-yo male with 8 prior lines (including autologous CAR-T) achieved CR at day 28, ongoing
  • No GvHD or Gr≥3 ICANS in both pivotal optimized vispa-cel subgroup (N=27) and CB-011 RDE cohort (N=12)
  • FDA alignment reached on ANTLER-3 phase 3 design (~250 patients, 2L LBCL not eligible for transplant/auto-CAR-T, PFS primary endpoint)
  • Initial dose expansion data for CB-011 in BCMA-naïve and -exposed patients expected H2 2026

Financial Impact

No revenue; company is pre-commercial. Data update supports pipeline valuation for vispa-cel and CB-011, two allogeneic CAR-T candidates with FDA RMAT, Fast Track, and Orphan Drug designations.

Risk Factors

  • Company has a history of net operating losses and needs additional capital to fund operations and the ANTLER-3 phase 3 trial
  • Phase 1 data from small single-arm cohorts may not be predictive of phase 3 outcomes or regulatory approval
  • Two treatment-related deaths reported across both trials (one vispa-cel-related IEC-HS, one CB-011-related hematotoxicity)
  • Pre-revenue biotech with high cash burn and dilutive financing risk

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001619856-26-000043
Document: crbu-20260611xexx992.htm0001619856-26-000043
Document: crbu-20260611xexx991.htm0001619856-26-000043
Document: 0001619856-26-000043-index-headers.html0001619856-26-000043
Document: 0001619856-26-000043-index.html0001619856-26-000043
Document: 0001619856-26-000043.txt0001619856-26-000043

Track record

13 reports on CRBU

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 7/10 Entry $0.4487 Now $0.3530 +21.33% settles Dec 7
  2. Oct 6, 20265w ago 8-K Bearish 7/10 Entry $0.6174 to $0.4444 Now $0.3530 +42.82% ▲ +28.02% +26.68% vs SPY
  3. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $1.34 to $0.5190 Now $0.3530 −73.66% ▼ −61.27% −60.71% vs SPY
  4. Jun 11, 202622w ago 8-K Bullish 6/10 Viewing Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
  5. Jun 11, 202622w ago Press Release Bullish 7/10 Entry $1.66 to $1.94 Now $0.3530 −78.73% ▲ +16.87% +14.98% vs SPY
  6. Jun 5, 202623w ago DEFA14A Neutral 2/10 Entry $1.84 to $1.83 Now $0.3530 −80.82% ▼ −0.54% −2.17% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $2.13 to $2.16 Now $0.3530 −83.43% ▲ +1.41% −3.55% vs SPY
  8. Mar 5, 202636w ago 8-K Mixed 5/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
  9. Mar 5, 202636w ago Press Release Mixed 6/10 Entry $1.82 to $1.95 Now $0.3530 −80.60% ▲ +7.14% +9.19% vs SPY
  10. Feb 28, 202637w ago Institutional Cluster Neutral 5/10 Entry $1.84 to $1.72 Now $0.3530 −80.82% ▼ −6.52% +1.42% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026